← FDA DRUG APPROVALS

FDA NDA · NDA218785

BRUKINSA

zanubrutinib

Sponsor: BEONE MEDICINES USA

APPLICATION
NDA218785
TYPE
NDA
ORIGINAL APPROVAL
2025-06-10
LATEST ACTION
2025-06-10
ROUTE
ORAL
DOSAGE FORM
CAPSULE, TABLET
MARKETING STATUS
Prescription

Products

BRUKINSAPrescription
ZANUBRUTINIB 80MG · CAPSULE · ORAL
BRUKINSA · ReferencePrescription
ZANUBRUTINIB 160MG · TABLET · ORAL

Approval history

2025-06-10Type 3 - New Dosage Form · Original · standardLabelAP
2025-06-10Type 3 - New Dosage Form · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →